Symbols / JANX $15.39 -0.45% Janux Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
JANX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Fundamentals
Scroll to Statements
Market Cap 936.20M Enterprise Value -8.23M Income -113.62M Sales 10.00M Book/sh 15.85 Cash/sh 15.89
Dividend Yield — Payout 0.00% Employees 109 IPO — P/E — Forward P/E -4.54
PEG — P/S 93.62 P/B 0.97 P/C — EV/EBITDA 0.05 EV/Sales -0.82
Quick Ratio 38.92 Current Ratio 39.04 Debt/Eq 2.31 LT Debt/Eq — EPS (ttm) -1.83 EPS next Y -3.39
EPS Growth — Revenue Growth — Earnings 2026-05-07 ROA -9.55% ROE -11.48% ROIC —
Gross Margin 0.00% Oper. Margin -15.77% Profit Margin 0.00% Shs Outstand 60.83M Shs Float 41.68M Short Float 18.20%
Short Ratio 6.68 Short Interest — 52W High 35.34 52W Low 12.12 Beta 2.81 Avg Volume 1.13M
Volume 584.73K Target Price $50.31 Recom Buy Prev Close $15.46 Price $15.39 Change -0.45%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$50.31
Mean price target
2. Current target
$15.39
Latest analyst target
3. DCF / Fair value
$-15.17
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.39
Low
$14.00
High
$100.00
Mean
$50.31

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-20 down Barclays Overweight → Underweight $14
2026-04-15 down UBS Buy → Neutral $15
2026-02-27 main Cantor Fitzgerald Overweight → Overweight $100
2026-02-27 main Guggenheim Buy → Buy $68
2026-01-20 down Clear Street Buy → Hold $12
2026-01-16 main Piper Sandler Overweight → Overweight $30
2025-12-17 main Barclays Overweight → Overweight $29
2025-12-02 main Stifel Buy → Buy $38
2025-12-02 main Clear Street Buy → Buy $32
2025-12-02 main B of A Securities Buy → Buy $49
2025-12-02 main Cantor Fitzgerald Overweight → Overweight $150
2025-12-02 main HC Wainwright & Co. Buy → Buy $45
2025-11-25 reit HC Wainwright & Co. Buy → Buy $70
2025-11-18 init Wolfe Research — → Peer Perform —
2025-11-07 main Barclays Overweight → Overweight $48
2025-09-17 init Barclays — → Overweight $47
2025-09-10 init Truist Securities — → Buy $100
2025-09-04 init Guggenheim — → Buy $72
2025-08-19 init Piper Sandler — → Overweight $42
2025-07-11 init Raymond James — → Outperform $65
News
RSS: Latest JANX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-02 GO WILLIAM M.D., PH.D. Officer — 44,000 $0.00 $0
2026-01-02 MEYER ANDREW HOLLMAN Officer — 1,879 $13.73 $25,799
2026-01-02 CAMPBELL DAVID ALAN Chief Executive Officer — 96,600 $0.00 $0
2026-01-02 CAMPBELL DAVID ALAN Chief Executive Officer — 8,072 $13.73 $110,829
2026-01-02 WINTER CHARLES M Chief Technology Officer — 28,600 $0.00 $0
2026-01-02 WINTER CHARLES M Chief Technology Officer — 2,401 $13.73 $32,966
2026-01-02 DIRAIMONDO THOMAS PH.D. Officer — 31,400 $0.00 $0
2026-01-02 DIRAIMONDO THOMAS PH.D. Officer — 2,505 $13.73 $34,394
2026-01-02 DOBEK MARIA Officer — 18,935 $0.00 $0
2026-01-02 DOBEK MARIA Officer — 1,462 $13.73 $20,073
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
10.00
-5.55%
10.59
+30.99%
8.08
-6.14%
8.61
Operating Revenue
10.00
-5.55%
10.59
+30.99%
8.08
-6.14%
8.61
Operating Expense
167.67
+53.21%
109.44
+35.00%
81.06
+7.08%
75.70
Research And Development
125.90
+84.09%
68.39
+24.52%
54.92
+2.77%
53.44
Selling General And Administration
41.77
+1.76%
41.05
+57.03%
26.14
+17.42%
22.26
General And Administrative Expense
41.77
+1.76%
41.05
+57.03%
26.14
+17.42%
22.26
Other Gand A
41.77
+1.76%
41.05
+57.03%
26.14
+17.42%
22.26
Total Expenses
167.67
+53.21%
109.44
+35.00%
81.06
+7.08%
75.70
Operating Income
-157.67
-59.51%
-98.85
-35.45%
-72.98
-8.78%
-67.09
Total Operating Income As Reported
-157.67
-59.51%
-98.85
-35.45%
-72.98
-8.78%
-67.09
EBITDA
-155.64
-60.80%
-96.79
-36.27%
-71.02
-7.21%
-66.25
Normalized EBITDA
-155.64
-60.80%
-96.79
-36.27%
-71.02
-7.21%
-66.25
Reconciled Depreciation
2.03
-1.50%
2.06
+5.37%
1.96
+132.46%
0.84
EBIT
-157.67
-59.51%
-98.85
-35.45%
-72.98
-8.78%
-67.09
Net Income
-113.62
-64.69%
-68.99
-18.36%
-58.29
+7.56%
-63.06
Pretax Income
-113.62
-64.69%
-68.99
-18.36%
-58.29
+7.56%
-63.06
Net Non Operating Interest Income Expense
44.04
+47.53%
29.85
+103.28%
14.69
+264.24%
4.03
Interest Expense Non Operating
—
—
—
—
Net Interest Income
44.04
+47.53%
29.85
+103.28%
14.69
+264.24%
4.03
Interest Expense
—
—
—
—
Interest Income Non Operating
44.04
+47.53%
29.85
+103.28%
14.69
+264.24%
4.03
Interest Income
44.04
+47.53%
29.85
+103.28%
14.69
+264.24%
4.03
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-113.62
-64.69%
-68.99
-18.36%
-58.29
+7.56%
-63.06
Net Income From Continuing Operation Net Minority Interest
-113.62
-64.69%
-68.99
-18.36%
-58.29
+7.56%
-63.06
Net Income From Continuing And Discontinued Operation
-113.62
-64.69%
-68.99
-18.36%
-58.29
+7.56%
-63.06
Net Income Continuous Operations
-113.62
-64.69%
-68.99
-18.36%
-58.29
+7.56%
-63.06
Normalized Income
-113.62
-64.69%
-68.99
-18.36%
-58.29
+7.56%
-63.06
Net Income Common Stockholders
-113.62
-64.69%
-68.99
-18.36%
-58.29
+7.56%
-63.06
Diluted EPS
—
-1.28
+3.03%
-1.32
+13.16%
-1.52
Basic EPS
—
-1.28
+3.03%
-1.32
+13.16%
-1.52
Basic Average Shares
—
53.75
+22.12%
44.02
+6.14%
41.47
Diluted Average Shares
—
53.75
+22.12%
44.02
+6.14%
41.47
Diluted NI Availto Com Stockholders
-113.62
-64.69%
-68.99
-18.36%
-58.29
+7.56%
-63.06
Line Item Trend 2021-12-31
Total Assets
—
Current Assets
—
Cash Cash Equivalents And Short Term Investments
—
Cash And Cash Equivalents
—
Other Short Term Investments
—
Receivables
0.00
Accounts Receivable
0.00
Accrued Interest Receivable
—
Prepaid Assets
2.05
Other Current Assets
2.05
Total Non Current Assets
—
Net PPE
—
Gross PPE
—
Accumulated Depreciation
—
Machinery Furniture Equipment
—
Construction In Progress
0.14
Other Properties
—
Other Non Current Assets
—
Total Liabilities Net Minority Interest
—
Current Liabilities
—
Payables And Accrued Expenses
—
Payables
—
Accounts Payable
—
Current Accrued Expenses
—
Pensionand Other Post Retirement Benefit Plans Current
—
Current Debt And Capital Lease Obligation
—
Current Capital Lease Obligation
—
Current Deferred Liabilities
5.16
Current Deferred Revenue
5.16
Other Current Liabilities
1.20
Total Non Current Liabilities Net Minority Interest
—
Long Term Debt And Capital Lease Obligation
—
Long Term Capital Lease Obligation
—
Non Current Deferred Liabilities
0.70
Non Current Deferred Revenue
0.70
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
—
Common Stock Equity
—
Capital Stock
—
Common Stock
—
Preferred Stock
—
Share Issued
—
Ordinary Shares Number
—
Treasury Shares Number
0.38
Additional Paid In Capital
—
Retained Earnings
—
Gains Losses Not Affecting Retained Earnings
—
Other Equity Adjustments
—
Total Equity Gross Minority Interest
—
Total Capitalization
—
Working Capital
—
Invested Capital
—
Total Debt
—
Capital Lease Obligations
—
Net Tangible Assets
—
Tangible Book Value
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-82.23
-87.69%
-43.81
+13.37%
-50.58
-17.83%
-42.92
Cash Flow From Continuing Operating Activities
-82.23
-87.69%
-43.81
+13.37%
-50.58
-17.83%
-42.92
Net Income From Continuing Operations
-113.62
-64.69%
-68.99
-18.36%
-58.29
+7.56%
-63.06
Depreciation Amortization Depletion
2.03
-1.50%
2.06
+5.37%
1.96
+132.46%
0.84
Depreciation
2.03
-1.50%
2.06
+5.37%
1.96
+132.46%
0.84
Depreciation And Amortization
2.03
-1.50%
2.06
+5.37%
1.96
+132.46%
0.84
Stock Based Compensation
40.22
+21.81%
33.02
+65.06%
20.00
+16.29%
17.20
Operating Gains Losses
—
—
—
—
Change In Working Capital
6.71
+880.15%
0.69
+110.45%
-6.55
-253.27%
4.28
Change In Receivables
—
—
—
0.00
Changes In Account Receivables
—
—
—
0.00
Change In Prepaid Assets
-0.83
+74.79%
-3.28
-1661.90%
0.21
+106.23%
-3.37
Change In Payables And Accrued Expense
7.27
+20.92%
6.01
+1598.75%
-0.40
-110.38%
3.86
Change In Accrued Expense
6.29
+42.11%
4.43
+752.80%
-0.68
-116.31%
4.16
Change In Payable
0.98
-38.32%
1.58
+471.84%
0.28
+194.22%
-0.29
Change In Account Payable
0.98
-38.32%
1.58
+471.84%
0.28
+194.22%
-0.29
Change In Other Working Capital
-0.00
+99.88%
-1.67
+68.15%
-5.24
-203.78%
5.05
Change In Other Current Assets
0.28
+173.60%
-0.38
+66.49%
-1.12
+11.89%
-1.27
Investing Cash Flow
-300.98
-16.65%
-258.02
-526.36%
-41.19
-170.70%
58.27
Cash Flow From Continuing Investing Activities
-300.98
-16.65%
-258.02
-526.36%
-41.19
-170.70%
58.27
Net PPE Purchase And Sale
-1.04
-190.53%
-0.36
+80.59%
-1.85
+71.30%
-6.45
Purchase Of PPE
-1.04
-190.53%
-0.36
+80.59%
-1.85
+71.30%
-6.45
Capital Expenditure
-1.04
-190.53%
-0.36
+80.59%
-1.85
+71.30%
-6.45
Net Investment Purchase And Sale
-299.94
-16.41%
-257.66
-554.90%
-39.34
-160.80%
64.71
Purchase Of Investment
-705.22
-49.86%
-470.58
-48.29%
-317.34
-7.80%
-294.39
Sale Of Investment
405.28
+90.35%
212.91
-23.41%
278.00
-22.58%
359.10
Financing Cash Flow
4.95
-99.31%
713.24
+1097.75%
59.55
+11809.60%
0.50
Cash Flow From Continuing Financing Activities
4.95
-99.31%
713.24
+1097.75%
59.55
+11809.60%
0.50
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
-0.35
-100.05%
698.27
+1135.21%
56.53
0.00
Common Stock Payments
-0.35
—
—
—
Repurchase Of Capital Stock
-0.35
—
—
—
Proceeds From Stock Option Exercised
5.29
-64.64%
14.97
+395.96%
3.02
+503.60%
0.50
Changes In Cash
-378.27
-191.95%
411.40
+1376.81%
-32.22
-303.36%
15.84
Beginning Cash Position
431.42
+2054.84%
20.02
-61.68%
52.24
+43.53%
36.40
End Cash Position
53.15
-87.68%
431.42
+2054.84%
20.02
-61.68%
52.24
Free Cash Flow
-83.28
-88.53%
-44.17
+15.74%
-52.42
-6.19%
-49.37
Amortization Of Securities
-17.57
-66.03%
-10.59
-37.68%
-7.69
-252.18%
-2.18
Common Stock Issuance
—
698.27
+1135.21%
56.53
0.00
Issuance Of Capital Stock
—
698.27
+1135.21%
56.53
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category